BACKGROUND: Barrett's metaplasia is a premalignant condition for which screening is recommended. AIMS/ METHODS: Annual screening endoscopies have been performed on all subjects suitable for surgery for many years. To examine the benefits to patients of continuing this policy 10 years' experience of screening for Barrett's oesophagus was reviewed. RESULTS: Of the 29,374 endoscopies performed over this period, Barrett's metaplasia was present in 1.4%. There was an approximate equal sex distribution with the majority of cases being identified in patients over 50 years old. Thirty five per cent of these patients were suitable to enter a yearly screening programme. During screening, the length of oesophagus involved did not vary over time. As a result of 379 endoscopies performed for screening purposes, only one patient was identified as developing carcinoma solely as a result of the screening programme. Two further patients had carcinoma identified as a result of progressive dysphagia requiring additional endoscopies. All three patients who developed carcinoma while in the screening programme had "long segment" (> 8 cm) regions of Barrett's metaplasia with a stricture present at the initial endoscopy. CONCLUSIONS: The poor yield from this screening programme suggests that the policy should be reconsidered. Resources may be better spent on focusing on patients who present with ulceration or stricture in addition to Barrett's metaplasia.
BACKGROUND:Barrett's metaplasia is a premalignant condition for which screening is recommended. AIMS/ METHODS: Annual screening endoscopies have been performed on all subjects suitable for surgery for many years. To examine the benefits to patients of continuing this policy 10 years' experience of screening for Barrett's oesophagus was reviewed. RESULTS: Of the 29,374 endoscopies performed over this period, Barrett's metaplasia was present in 1.4%. There was an approximate equal sex distribution with the majority of cases being identified in patients over 50 years old. Thirty five per cent of these patients were suitable to enter a yearly screening programme. During screening, the length of oesophagus involved did not vary over time. As a result of 379 endoscopies performed for screening purposes, only one patient was identified as developing carcinoma solely as a result of the screening programme. Two further patients had carcinoma identified as a result of progressive dysphagia requiring additional endoscopies. All three patients who developed carcinoma while in the screening programme had "long segment" (> 8 cm) regions of Barrett's metaplasia with a stricture present at the initial endoscopy. CONCLUSIONS: The poor yield from this screening programme suggests that the policy should be reconsidered. Resources may be better spent on focusing on patients who present with ulceration or stricture in addition to Barrett's metaplasia.
Authors: S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel Journal: Gastroenterology Date: 1984-10 Impact factor: 22.682
Authors: Corrado Pedrazzani; Filippo Catalano; Mara Festini; Germana Zerman; Anna Tomezzoli; Andrea Ruzzenente; Alfredo Guglielmi; Giovanni de Manzoni Journal: World J Gastroenterol Date: 2005-03-28 Impact factor: 5.742
Authors: Xiaohong Li; Patricia C Galipeau; Thomas G Paulson; Carissa A Sanchez; Jessica Arnaudo; Karen Liu; Cassandra L Sather; Rumen L Kostadinov; Robert D Odze; Mary K Kuhner; Carlo C Maley; Steven G Self; Thomas L Vaughan; Patricia L Blount; Brian J Reid Journal: Cancer Prev Res (Phila) Date: 2013-11-19
Authors: Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe Journal: Ann Surg Date: 2007-07 Impact factor: 12.969
Authors: Madhav Desai; David A Lieberman; Kevin F Kennedy; Nour Hamade; Prashanthi Thota; Sravanthi Parasa; Venkat Subhash Gorrepati; Ajay Bansal; Neil Gupta; Srinivas Gaddam; Patrick E Young; Sharad Mathur; Fouad J Moawad; Brooks D Cash; Richard Sampliner; John J Vargo; Gary W Falk; Prateek Sharma Journal: Gastrointest Endosc Date: 2018-10-17 Impact factor: 9.427